Get all your news in one place.
100’s of premium titles.
One app.
Start reading
Reuters
Reuters
Business

Japan's PeptiDream to work with Merck in developing COVID-19 therapies

The Merck logo is seen at a gate to the Merck & Co campus in Linden, New Jersey, U.S., July 12, 2018. REUTERS/Brendan McDermid

Japanese drug-discovery company PeptiDream Inc said on Friday it would collaborate with Merck & Co in developing COVID-19 therapies.

The companies will work to develop peptide therapeutics that may be effective against multiple coronavirus strains, they said in a release. The agreement builds on a research and licensing partnership announced in 2015.

PeptiDream specialises in constrained peptides, types of amino acids that can carry various cargoes to specific types of cells.

(Reporting by Rocky Swift; Editing by Christian Schmollinger)

Sign up to read this article
Read news from 100’s of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.